Combined estrogen-progestogen contraceptives (oral contraceptives or OCs) and progestogen-only contraceptives (POCs) are synthetic steroids that bind to steroid hormone receptors, which are widespread throughout the body. They have a profound effect on cellular physiology. Combined OCs have been classified by the International Agency for Research on Cancer (IARC) as Group 1 carcinogens, but their findings have not been updated recently. In order to update the information and better understand the impact that OCs and POCs have on the risk of development of cancers, a comprehensive literature search was undertaken, focusing on more recently published papers. In agreement with the IARC, the recent literature confirms an increased risk of breast cancer and cervical cancer with the use of OCs. The recent literature also confirms the IARC conclusion that OCs decrease the risk of ovarian and endometrial cancers. However, there is little support from recent studies for the IARC conclusion that OCs decrease the risk of colorectal cancer or increase the risk of liver cancer. For liver cancer, this may be due to the recent studies having been performed in areas where hepatitis is endemic. In one large observational study, POCs also appear to increase the overall risk of developing cancer. OCs and POCs appear to increase the overall risk of cancer when carefully performed studies with the least intrinsic bias are considered.
Combined estrogen-progestogen oral contraceptives (OCs) have been classified as Group 1 carcinogens by the World Health Organization (Cogliano et al. 2005) . They are comprised of potent synthetic steroids that act on the estrogen or progesterone receptors. It is estimated that 15.9 percent of all women in the United States aged fifteen to forty-four, or ten million women, are currently using OCs, while another 2.6 percent are using progestogen-only contraceptives (POCs; Centers for Disease Control 2018). Of women aged fifteen to forty-four, 79.3 percent have at some point used OCs. These steroid agonists have numerous effects on the body as estrogen and progesterone receptors are widely expressed in the body, especially in reproductive tissues. However, they are also known to be expressed in immune cells and many other tissues (see Genecards ESR1; Genecards ESR2; Genecards PGR). As such, it can be expected that OCs and POCs can have direct or indirect effects on numerous cells and tissues. This can include both short-term effects (such as prevention of ovulation and thinning of the endometrium) and long-term effects (as a result of effects on cellular growth, metabolism, immunomodulation, etc.). Two long-term effects of the use of OCs and POCs are impacts on cell division and immune responses, both of which can increase or decrease the susceptibility to cancer. The IARC classification of OCs as Group 1 carcinogens was an upgrade from their previous classification. (IARC 2007) . The data for this monograph were updated a few years later and include studies published up to May 2008. Their conclusion was:
There is sufficient evidence in humans for the carcinogenicity of combined estrogen-progestogen OCs. Combined estrogen-progestogen OCs cause cancer of the breast, in situ and invasive cancer of the uterine cervix, and cancer of the liver. For cancer of the endometrium, ovary, and colorectum, there is evidence suggesting lack of carcinogenicity. An inverse relationship has been established between exposure to combined estrogen-progestogen OCs and cancer of the endometrium, ovary, and colorectum.
There is sufficient evidence in experimental animals for the carcinogenicity of several combinations of estrogen-progestogen used in OCs. Combined estrogen-progestogen OCs are carcinogenic to humans (Group 1; IARC 2012).
In order to update the information and better understand the impact that OCs and POCs have on the risk of development of cancers, a comprehensive literature search was undertaken, focusing on papers published since 2005. As the chemical components of OCs have changed over the years, the decision was made to focus on the most recent literature as this was felt to be most relevant to the currently available agents. We also sought to compare our results with the most recently published IARC monograph and reevaluate their conclusions with the most recent data.
Materials and Methods
The objective of this literature survey was to determine whether OCs and POCs alter the susceptibility for cancers. The search was performed in the PUBMED database for the following terms: Title for: cancer A total of 2,422 papers were returned. The search was further limited to humans, and 2,195 papers were returned. Titles were reviewed back to the year 2000, and a total of 434 papers were selected for more in-depth review. The papers published since 2005 were the primary focus of this review.
Each paper was rated based on the parameters noted in the strengthening the reporting of observational studies in epidemiology (STROBE) statement (von Elm et al. 2007 ). This included the following:
Background and rationale provided? Objectives stated? Key elements of study design presented? Setting, locations, and relevant dates described? Eligibility criteria and the sources and methods of selection of participants provided? 1 Matching criteria and number of exposed/ unexposed/controls provided? Diagnostic criteria, outcomes, exposures, predictors, potential confounders, and effect modifiers provided? Sources of data and details of methods of assessment provided? Any efforts to address potential sources of bias? Rationale for the study size provided? Information on how quantitative variables were handled in the analyses? Statistical methods described, including those that control for confounding? Methods used to examine subgroups and interactions described? Missing data addressed? Other analyses reported (i.e., subgroups)? Limitations of the study discussed, including magnitude and direction of potential bias? Source of funding provided?
Each item was assigned a maximum score of 1, and the result converted into a percentage. Also noted for each study were the odds ratio (OR), relative risk (RR), or hazard ratio (HR), and the 95 percent confidence interval. Briefly, for RR, if the population under study is divided into those with and without exposure to a steroidal contraceptive and is further divided into those who subsequently develop the disease or do not develop the disease, the RR is the percentage of those in the exposed group with the disease divided by the percentage of those in the unexposed group who develop the disease. The OR is the proportion of those in the exposed group who did versus did not develop the disease divided by the proportion of those in the unexposed group who did versus did not develop the disease (Altman 1991; Deeks and Higgins 2010; Pagano and Gauvreau 2000; Parshall 2013) . A HR is the ratio of the hazard rates corresponding to the conditions described by two levels of an explanatory variable (Spruance et al. 2004 ). For example, if the death rate in population A is twice that in population B, the HR for A versus B would be 2. For all studies, if both unadjusted and multivariable-adjusted ORs, RRs, or HRs were stated, the multivariable-adjusted ORs, RRs, or HRs were summarized here.
Results

Breast Cancer
Breast cancer is the most commonly diagnosed cancer (excluding nonmelanoma skin cancers) in women in developed nations, including the United States, with 1.7 million cases diagnosed worldwide annually. It accounts for 30 percent of all new cancer diagnoses in women (https://www.breastcancer.org/ symptoms/understand_bc/statistics). According to the Surveillance, Epidemiology and End Results (SEER) statistics (https://seer.cancer.gov/statfacts/ html/breast.html), it is estimated that there are about 3,418,000 women with invasive breast cancer in the United States. There will be about 266,000 new cases of breast cancer in 2018, accounting for 15.3 percent of all new cancer cases, with about 41,000 deaths, accounting for 6.7 percent of all cancer deaths. The five-year survival for breast cancer is 90 percent. Nulliparity or late childbearing and high body mass index are risk factors for breast cancer as
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The Linacre Quarterly 85 (4) is exposure to OCs and hormone replacement therapy (HRT). Any risk factors that are controllable should be minimized. The data for breast cancer are shown in Table 1 , split into cohort studies (Table 1) , meta-analyses (Table 2) , and case-control studies (Table 3) Kotsopoulos et al. 2014 ) and the risk increased by 11 percent for each additional year of use.
The studies that looked at recent use (within one to five years) or current use of OCs in premenopausal women showed the most dramatic increased risk of breast cancer. In a case-control study, women aged twenty to forty-nine years with the use of OCs within a year had an increased risk of breast cancer (OR ¼ 1.5; 95 percent CI [1.3, 1.9]; Beaber, Buist, et al. 2014 ). The same study showed an increase in risk depending on the formulation, with triphasic OCs carrying a markedly increased risk (OR ¼ 3.1; 95 percent CI [1.4, 4.7] ). In another large case-control study of women aged twenty to fortyfive years, use of OCs for a year or more resulted in a 2.5-fold increased risk of triple negative breast cancer (95 percent CI [1.4, 4.3]) but not for the receptor positive breast cancers. In the same study, women aged forty years or younger with a year or more use of OCs had a higher RR of triple negative breast cancer (RR ¼ 4.2; 95 percent CI [1.9, 9 .3]; Dolle et al. 2009 (Bethea et al. 2015) .
In a French study (DeLort et al. 2007) (Mørch et al. 2017) . They found the increased risk persisted after discontinuing use if OCs were used for five years or more. These investigators also found an increased risk in current or recent use of the progestogen-only intrauterine device (RR ¼ 1.21; 95 percent CI [1.11, 1.33]).
There is very little literature on the risk of cancer with the POCs. Only 2 percent of women report the use or ever use of POCs. In a study of 4,816 women with breast cancer, 135 of whom had used POCs, there was a better long-term survival with POC use (Samson et al. 2017) as compared with combined oral contraceptive(s) (COC) use. However, the investigators acknowledged the small sample.
OCs were illegal until 1999 in Japan, and as of 2015, only 5 percent of women in that country use OCs. In a recent Japanese study of 155 cases of breast cancer, there was no increased risk of breast cancer with OC use (Ichida et al. 2015 
Cervical Cancer
According to the SEER statistics (https://seer.cancer. gov/statfacts/html/cervix.html), it is estimated that there are 257,524 women in the United States with cervical cancer. There will be about 13,000 new cases of cervical cancer in 2018, with about 4,000 deaths. The five-year survival for cervical cancer is 66 percent. The data for cervical cancer are shown in Table 4 . All studies appear to be in agreement that there is an increased risk of cervical cancer in users of OCs (OR apparently about 1.05 per year of use), and this risk increases with duration of use. Current use appears to confer a higher risk than past use, and the risk for invasive cancer shows the highest increase in risk (Roura et al. 2016) . One casecontrol study (McFarlane-Anderson et al. 2008 ) and one meta-analysis (International Collaboration 2007) also showed an increased risk with POCs. Thus, there does appear to be an increased risk of cervical cancer in users of OCs or POCs, and the risk appears to increase with the duration of use.
Liver Cancer
According to the SEER statistics (https://seer.cancer. gov/statfacts/html/livibd.html), it is estimated that there are about 72,000 people with liver cancer in the United States including about 18,000 women. There will be about 42,000 new cases of liver cancer in 2018 (about 11,000 women), with about 30,000 deaths (about 7,800 women). The five-year survival for liver cancer is 18 percent. The data for liver cancer are shown in Table 5 One meta-analysis of fourteen case-control studies and three cohort studies failed to show a significant difference, although separate analysis of the case-control studies did show a significantly increased OR (1.55) . Metaanalysis of the three cohort studies did not show an increased risk. One more recent cohort study did not show a significantly increased risk, while an older case-control study also did not. Thus, the recent studies reviewed do not confirm the earlier studies noted by IARC which concluded that OCs increase the risk of liver cancer. However, this difference may be attributed to the specific nature of the IARC findings. They noted that the risk of liver cancer was increased only in populations that had a low incidence of hepatitis B infection and chronic liver disease. The meta-analysis by noted, "Chronic infections with hepatitis B or C virus and alcohol consumption are established risk factors for liver cancer. Few studies in original data clarified its effect. Thus, inadequate control of the confounders might mask the true risk" (p. 6). In the cohort study (McGlynn et al. 2015) , they noted that of eightyeight hepatocellular carcinoma cases evaluated, 31.7 percent were positive for anti-hepatitis C virus while another 2.3 percent were positive for hepatitis B surface antigen. Thus, these more recent studies appear to have been in populations where hepatitis virus infection was prevalent. Therefore, they do not adequately evaluate populations with a low incidence of hepatitis virus infection and chronic liver Tables 9, 10 and 11. Most of the studies showed a significant decrease in risk with the ever use of OCs. Thus, there does appear to be a protective effect of OCs on the risk of ovarian cancer. Based on the most reliable studies, the RR for ever use of OCs for ovarian cancer is 0.84-0.86 (Tsilidis et al. 2011; Fortner et al. 2015) . The RR per five years of use is 0.87 (0.82-0.93). For those with BRCA1 or BRCA2 mutations, the risk reduction is even greater: 0.21-0.63 (Kotsopoulos et al. 2015; McLaughlin et al. 2007; Perri et al. 2015) . A couple of studies (Kurta et al. 2012; Greer et al. 2005 high-quality cohort studies (counting the nurses health study I (NHSI) and nurses health study II (NHSII) study analyses as separate studies) failed to show any relationship between OC use and colorectal cancer. Two of the three case-control studies also failed to show an effect. Thus, these recent data do not appear to confirm prior studies, noted by IARC, that the use of OCs may reduce the risk of colorectal cancer. Interestingly, one study of anal cancer appeared to show an increased risk (Coffey et al. 2015) .
Skin Cancer
According to the SEER statistics (https://seer.cancer. gov/statfacts/html/melan.html), it is estimated that there are about 1,222,000 people in the United States with melanoma of which about 455,000 are women.
There will be about 91,000 new cases of melanoma in 2018 (about 34,000 new cases in women), with about 9,000 deaths (about 3,500 in women). The five-year survival for melanoma is 92 percent. The data for melanoma are shown in Table 15 . Since 2005, only one review paper was identified which summarized the data from prior meta-analyses which did not show an increase or decrease in the risk of melanoma from the use of OCs. Thus, there does not appear to be convincing evidence of a decreased or increased risk of melanoma in users of OCs. Incidentally, one cohort study was evaluated which looked at the effect of OCs on nonmelanoma skin cancer (basal cell and squamous cell cancer). No effect of OCs was noted.
Thyroid Cancer
According to the SEER statistics (https://seer.cancer. gov/statfacts/html/thyro.html), it is estimated there are about 766,000 people in the United States with thyroid cancer of which approximately 571,000 are women. There will be about 54,000 new cases of thyroid cancer in 2018 (about 40,000 new cases in women), with about 2,000 deaths (about 1,500 in women). The five-year survival for thyroid cancer is 98 percent. The data for thyroid cancer are shown in Table 16 . Most of the studies showed a lack of effect of OC use on the incidence of thyroid cancer, with the exception of the Schonfeld study (Schonfeld et al. 2011 ) that showed a significantly decrease RR for individuals using OCs for ten plus years and a meta-analysis (Wu and Zhu 2015) , which included the Schonfeld study. However, two other metaanalyses showed no effect, and in the group that did show a significant effect in the Schonfeld study, only fourteen cases of thyroid cancer were seen. In addition, in the Wu meta-analysis, they claimed to include 1,906 cases and about 1.3 million controls. Their analysis was clouded by the fact that they compared primarily longest duration of OC use versus shortest duration of use. This analysis appears to have excluded most cases they claimed to have analyzed. For example, in their inclusion of the Schonfeld study, they claimed 312 cases in 187,865 subjects, but only used the RR for those with ten plus years of use (fourteen cases and 17,269 subjects in total). They also weighted the studies, but it is unclear how they were weighted. Overall, there is no clear effect of OC use on the incidence of thyroid cancer.
Lung Cancer
According to the SEER statistics (https://seer.cancer. gov/statfacts/html/lungb.html), it is estimated that there are about 541,000 people with lung cancer in the United States, including about 232,000 women.
There will be about 234,000 new cases of lung cancer in 2018 (about 100,000 women), with about 154,000 deaths (about 66,000 women). The fiveyear survival for lung cancer is 19 percent. The data for lung cancer are shown in Table 17 . Most of the studies did not show a significant increase or decrease in risk with the ever use of OCs, although one study showed a decreased risk with ever use (Pesatori, Carugno, Consonni, Caporaso, et al. 2013) . Thus, there does not appear to be an effect of OCs on the risk of lung cancer.
Kidney Cancer
According to the SEER statistics (https://seer.cancer. gov/statfacts/html/kidrp.html), it is estimated that there are about 505,000 people in the United States with kidney cancer including about 169,000 women.
There will be about 65,000 new cases of kidney cancer in 2018 (about 22,000 women), with about 15,000 deaths (about 5,000 women). The five-year survival for kidney cancer is 75 percent. The data for kidney cancer are shown in Table 18 . None of the studies show a significant increased risk with the ever use of OCs, and although one study showed a decreased risk with over ten years of use (Karami et al. 2013 ), others did not (Kabat et al. 2007 ). Thus, there does not appear to be an effect of OCs on the risk of kidney cancer. Table 19 . While one case-control study showed a decreased risk, another case-control study and a large cohort study failed to show a significant effect. Thus, there does not appear to be convincing evidence of a decreased or increased risk of bladder cancer in users of OCs.
Gastric Cancer
According to the SEER statistics (https://seer.cancer. gov/statfacts/html/stomach.html), it is estimated that there are about 98,000 people with stomach (gastric) cancer in the United States of which about 34,000 are women. There will be about 26,000 new cases of gastric cancer in 2018 (about 9,000 in women), with about 11,000 deaths (about 3,700 women). The fiveyear survival for gastric cancer is 31 percent. The data for gastric cancer are shown in Table 20 . Although one cohort study showed a decrease in the RR of gastric cancer with OCs ), other studies did not. Thus, there does not appear to be an effect of OCs on the risk of gastric cancer.
Pancreatic Cancer
According to the SEER statistics (https://seer.cancer. gov/statfacts/html/pancreas.html), it is estimated that there are about 69,000 people in the United States with pancreatic cancer, including about 30,000 women. There will be about 55,000 new cases of pancreatic cancer in 2018 (about 24,000 women), with about 44,000 deaths (about 19,000 women). The five-year survival for pancreatic cancer is 9 percent. The data for pancreatic cancer are shown in Table 21 . None of the studies show a significant increased risk with the ever use of OCs, and although one study showed an increased risk with over ten years of use (Zhang et al. 2010 ), others did not (Teras et al. 2005) . Thus, there does not appear to be an effect of OCs on the risk of pancreatic cancer. ORs from two meta-analyses of melanoma reviewed.
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Lynch Syndrome
Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer, is a genetic disease caused by alterations in genes involved in DNA mismatch repair. Lynch syndrome accounts for 3-5 percent of all cases of colorectal cancer (https://www.can cer.net/cancer-types/lynch-syndrome). The data for Lynch syndrome are shown in Table 22 . One study evaluated endometrial cancer in patients with Lynch syndrome (Dashti et al. 2015) , and similar to overall effects in endometrial cancer, they found a decreased incidence in ever users of OCs. Another paper looking at all extracolonic tumors also showed a decreased incidence in patients with the mutation, but interestingly showed a significant increase in mutation negative relatives (Blokhuis et al. 2010) . Thus, in patients with Lynch syndrome, OCs appear to convey some protection against extracolonic cancers.
Multiple Cancers
Several papers examined multiple cancer types in single studies (Table 23 ). There were some papers that examined the incidence of all cancers in women exposed to steroidal contraceptives. One group looked at the incidence of all cancers in women using the levonorgestrel intrauterine-releasing system for heavy menstrual bleeding in Finland (Soini et al. 2014 (Hannaford et al. 2007 ) evaluated all-cause mortality and cancer-related mortality in women on OCs. They found a decreased overall mortality (RR ¼ 0.9; 95 percent CI [0.86, 0.95] ) and cancer- In our evaluation here, we emphasized the most recent primary studies, giving greater weight to cohort studies which lack some of the intrinsic selection biases present in case-control studies. Meta-analyses are also noted but, as they typically include older studies, were given less weight as these had been reviewed by IARC previously.
In agreement with IARC, the recent data confirm an increased risk of breast cancer with the use of OCs (Table 1) . This includes data from some very recent, large cohort studies (Mørch et al. 2017; Heikkinen et al. 2016; Poosari et al. 2014 ) with RRs ranging from 1.2 to 1.37. Since breast cancer is by far the most common cancer in women, affecting one in eight women, this translates into a substantial number of additional cancer cases. In addition, a large registry study of POCs (Soini et al. 2014, Table 22) showed an increased RR for breast cancer of 1.19. Increased duration of use also increases the risk of breast cancer for OCs as does use early in life (March 2017) . The risk does decrease with increasing time since last use.
The IARC evaluation of an increased risk of cervical cancer with OCs is also supported especially by a large, high-quality cohort study (Roura et al. 2016; Table 4 ). This showed in particular a higher risk for invasive cervical cancer and a higher risk with current use. In contrast, the recent literature on liver cancer did not support an increased risk with OCs (Table 5 ). This discrepancy is likely accounted for by the observation by IARC that the increased risk for liver cancer was only apparent in populations with a low risk of hepatitis and chronic liver disease. These recent studies appeared to be in populations where hepatitis and chronic liver disease are endemic. This likely masked the effect of the OCs. Thus, there does not appear to be sufficient new evidence to overturn IARCs findings of an increased risk of liver cancer with OCs in populations where hepatitis and chronic liver disease are not endemic. Several cancers were noted by IARC to have a lower risk with the use of OCs. This includes endometrial cancer (Table 6 ), ovarian cancer (Table 9) , and colorectal cancer (Table 12 ). The IARC findings on endometrial cancer and ovarian cancer are supported by the recent studies reviewed. All the recent cohort studies of endometrial cancer show a reduced risk with OC use, and the risk further decreases with longer use with an annualized RR estimated as 0.95 (Hüsing et al. 2016) . Similarly, for ovarian cancer, risk is reduced with OCs, and this further decreases with longer use with an annualized RR estimated as 0.94 (Gay et al. 2015) . The relatively low frequency of these cancers in comparison to breast cancer would suggest that the overall cancer risk for women would still be increased by OCs.
One discrepancy between recent studies and the IARC review is regarding colorectal cancer (Table  12 ). The most recent IARC monograph notes that an inverse relationship has been established between exposure to OCs and colorectal cancer. However, since that publication, several high-quality cohort studies have been published, which do not support a significant effect (Tsilidis et al. 2010; Zervoudakis et al. 2011; Charlton et al. 2015; Brändstedt et al. 2014) . One study evaluating anal cancer showed an increased RR with OC use (Coffey et al. 2015) . This suggests that the risk profile for colorectal cancer with the use of OCs may be changing with newer preparations. IARC should examine this more recent data and consider revising the findings with regard to colorectal cancer.
No other cancer type was found in these analyses to have an increased or decreased risk of developing with the use of OCs. There were a few papers that evaluated overall cancer risk. One looked at a POC, specifically evaluating the levonorgestrel intrauterine-releasing system for heavy menstrual bleeding (Soini et al. 2014; Table 22 ). They found an overall RR for the development of any cancer of 1.07 with one or more prescription and 1.2 with 2 or more prescriptions. This was almost entirely from the increase in breast cancer risk (RR ¼ 1.19 with one of more prescription and RR ¼ 1.4 with two or more prescriptions). Similar to OCs, they saw a decrease in the risk of endometrial and ovarian cancer (RR of 0.46 and 0.6, respectively, with one or more use). In contrast, a similar study of OCs (Hannaford et al. 2007) showed an overall significantly decreased risk for all cancers (RR ¼ 0.88) but oddly showed a significantly increased RR with the past use of OCs (RR ¼ 1.22). This study suffered from a very high dropout rate, making the results suspect. It was also funded by several pharmaceutical companies who sell OCs and POCs.
There are also moral implications from these findings. As noted by Blessed Pope Paul VI (1968) , contraceptives separate the unitive and procreative aspects of the marital act with many negative predicted consequences. OCs and POCs suffer from an additional moral problem: They treat a normal functioning body system (the female reproductive system) as if it were a disease. Potent steroids have a profound effect on the physiology of multiple cells, tissues, and organs in the female body. These extend beyond inhibiting ovulation and thinning the endometrium. OCs and POCs work on other epithelial cells, especially in the mammary glands and cervix, to increase their proliferation. With each cell division, there is a chance for mutation, which increases the risk of carcinogenesis. While the scientific basis for OCs and POCs acting as Group 1 carcinogens may be apparent, the moral aspect may be less so. Because of the profound unity of body, mind, and spirit of the human person, things that affect one will affect the others. Thus, spiritual insults to the person (i.e., sins) will invariably have sociological, psychological, and physical consequences. Contraception in and of itself disrupts the most fundamental of human interactions: the marital act. Contraception attempts to separate the unitive and procreative aspects of the marital act. It logically follows that human interactions will be directly affected. Indeed, a variety of sociological consequences have been attributed to the use of contraception (e.g., increased divorce rates, the use of women as objects, a coarsening of morality). Steroidal contraceptives also suffer from the moral evil of treating fertility as a disease. This is against the integrity of the human person and the ethical principle of respect for persons, not to mention the imperative to do no harm (i.e., inhibiting the normal functioning of a bodily system). It therefore logically follows that physical harm may come to women. This is seen in the many, common side effects of OCs and POCs, which are detailed in the individual prescribing information. Increases in several types of cancer are some of the most serious consequences of OC/POC use.
In our society today, there are many effective, natural alternatives to the use of OCs and POCs. Physicians are morally obligated to treat the whole patient as well as to do no harm. Promoting the use
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The Linacre Quarterly 85(4) of natural methods of family planning and fertility awareness and discouraging the use of carcinogenic OCs and POCs more effectively diminish harm and respect the integrity of the patient as a human person.
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